These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 16311733)

  • 21. HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production.
    Simeone AM; Broemeling LD; Rosenblum J; Tari AM
    Oncogene; 2003 Oct; 22(43):6739-47. PubMed ID: 14555987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.
    Garrett JT; Sutton CR; Kuba MG; Cook RS; Arteaga CL
    Clin Cancer Res; 2013 Feb; 19(3):610-9. PubMed ID: 23224399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
    Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castilló B; Pérez-Martínez MC; Cufí S; Del Barco S; Bernado L; Brunet J; López-Bonet E; Menendez JA
    Int J Oncol; 2010 Sep; 37(3):669-78. PubMed ID: 20664936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selection and characterization of HER2/neu-binding affibody ligands.
    Wikman M; Steffen AC; Gunneriusson E; Tolmachev V; Adams GP; Carlsson J; Ståhl S
    Protein Eng Des Sel; 2004 May; 17(5):455-62. PubMed ID: 15208403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Predictive value of Her2/neu expression/amplification for the targeted treatment of breast cancer].
    Lehr HA; Schaefer SC; Delaloye JF
    Rev Med Suisse; 2009 Jul; 5(211):1525-9. PubMed ID: 19694364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2.
    Jäger M; Schoberth A; Ruf P; Hess J; Lindhofer H
    Cancer Res; 2009 May; 69(10):4270-6. PubMed ID: 19435924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
    Hortobagyi GN
    Semin Oncol; 2001 Dec; 28(6 Suppl 18):43-7. PubMed ID: 11774205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments.
    Tang Y; Wang J; Scollard DA; Mondal H; Holloway C; Kahn HJ; Reilly RM
    Nucl Med Biol; 2005 Jan; 32(1):51-8. PubMed ID: 15691661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate.
    Eddy SF; Kane SE; Sonenshein GE
    Cancer Res; 2007 Oct; 67(19):9018-23. PubMed ID: 17909003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategies to target HER2/neu overexpression for cancer therapy.
    Chen JS; Lan K; Hung MC
    Drug Resist Updat; 2003 Jun; 6(3):129-36. PubMed ID: 12860460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer.
    Hahn T; Bradley-Dunlop DJ; Hurley LH; Von-Hoff D; Gately S; Mary DL; Lu H; Penichet ML; Besselsen DG; Cole BB; Meeuwsen T; Walker E; Akporiaye ET
    BMC Cancer; 2011 Nov; 11():471. PubMed ID: 22044845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer.
    Sawaki M; Ito Y; Tada K; Mizunuma N; Takahashi S; Horikoshi N; Kasumi F; Akiyama F; Sakamoto G; Imai T; Nakao A; Hatake K
    Tumori; 2004; 90(1):40-3. PubMed ID: 15143970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
    Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
    Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells.
    Marches R; Uhr JW
    Int J Cancer; 2004 Nov; 112(3):492-501. PubMed ID: 15382077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+ tumors.
    Hardee ME; Eapen RJ; Rabbani ZN; Dreher MR; Marks J; Blackwell KL; Dewhirst MW
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):219-28. PubMed ID: 18365198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.
    Fessler SP; Wotkowicz MT; Mahanta SK; Bamdad C
    Breast Cancer Res Treat; 2009 Nov; 118(1):113-24. PubMed ID: 19415485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway.
    Way TD; Kao MC; Lin JK
    J Biol Chem; 2004 Feb; 279(6):4479-89. PubMed ID: 14602723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel anti-HER2 antibody GB235 reverses Trastuzumab resistance in HER2-expressing tumor cells in vitro and in vivo.
    Shu M; Yan H; Xu C; Wu Y; Chi Z; Nian W; He Z; Xiao J; Wei H; Zhou Q; Zhou JX
    Sci Rep; 2020 Feb; 10(1):2986. PubMed ID: 32076029
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.